Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2215/CJN.0000000781 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Safety of Factor XI Inhibition With Abelacimab in Atrial Fibrillation by Kidney Function: A Prespecified Analysis of the AZALEA-TIMI 71 Randomized Clinical Trial.
JAMA Cardiol
September 2025
TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
Importance: Chronic kidney disease is common in patients with atrial fibrillation (AF) and is associated with higher rates of bleeding with anticoagulation. In the AZALEA-TIMI 71 randomized clinical trial, abelacimab, a novel factor XI inhibitor, reduced rates of major or clinically relevant nonmajor (CRNM) bleeding compared with rivaroxaban in patients with AF.
Objective: To examine the safety of abelacimab vs rivaroxaban across a range of kidney function.
In silico prediction of optimal multifactorial intervention in chronic kidney disease.
J Transl Med
August 2025
Mosaiques Diagnostics GmbH, Rotenburger Straße 20, 30659, Hannover, Germany.
Background: Chronic kidney disease (CKD) contributes to global morbidity and mortality. Early, targeted intervention can help mitigate its impact. CK273 is a urinary peptide classifier previously validated in a prospective clinical trial for the early detection of nephropathy.
View Article and Find Full Text PDFSpironolactone in patients on chronic haemodialysis at high risk of adverse cardiovascular outcomes (ALCHEMIST): a multicentre, double-blind, randomised, placebo-controlled trial and updated meta-analysis.
Lancet
August 2025
Service de Néphrologie CHRU de Nancy, Nancy, France; F-CRIN INI-CRCT, Nancy, France.
Background: No pharmacological therapy has been shown with certainty to improve the cardiovascular prognosis in patients with kidney failure on chronic haemodialysis. We aimed to investigate the effects of the steroidal mineralocorticoid receptor antagonist spironolactone on cardiovascular outcomes in patients on haemodialysis who are at high risk of cardiovascular events.
Methods: ALCHEMIST was an investigator-initiated, multicentre, double-blind, randomised, placebo-controlled, event-driven trial conducted at 64 university hospitals, general hospitals, and non-profit or private practice dialysis centres in France, Belgium, and Monaco.
Comparison of the measurement properties of EQ-5D-5L and SF-6Dv2 in Chinese patients on dialysis.
Health Qual Life Outcomes
July 2025
Health Economics Unit, Department of Clinical Sciences (Malmö), Forum Medicum, Lund University, Sölvegatan 19, Lund, 223 62, Sweden.
Background: Measuring health-related quality of life (HRQoL) in dialysis patients is essential for clinical assessment and economic evaluation. Despite the emergence and increasing use of updated instruments, evidence comparing their performance in Chinese dialysis patients remains limited. The aim of this study was to compare the measurement properties of the EQ-5D-5L and the SF-6Dv2 instruments in Chinese patients on dialysis and to provide a reference for future utility scale choice for Chinese dialysis patients.
View Article and Find Full Text PDFSplenic artery aneurysmal rupture at 24 weeks gestation in a patient with successful in vitro fertilization and embryo transfer after kidney transplantation: a case report.
BMC Nephrol
July 2025
Department of Nursing, The First Affiliated Hospital, Zhejiang University School of Medicine, 79 Qingchun Rd, Shangcheng District, Hangzhou, 310003, China.
Background: Kidney transplantation represents a critical intervention for end-stage renal disease on a global scale. Many women of childbearing age who have received a kidney transplant express a significant desire to conceive. Nevertheless, the occurrence of in vitro fertilization-embryo transfer (IVF-ET) following kidney transplantation remains infrequent.
View Article and Find Full Text PDF